Form 4: Medpace Holdings CEO August J. Troendle Reports Stock Sales
SEC Form 4
Medpace Holdings CEO August J. Troendle reported the sale of company stock in two transactions on May 8 and May 9, 2024.
Summary
- August J. Troendle, CEO of Medpace Holdings, Inc., reported the sale of 4,782 shares of common stock on May 8, 2024, at a weighted average price of $400.58.
- He also sold 3,486 shares of common stock on May 9, 2024, at a weighted average price of $400.17.
- Following these transactions, Troendle directly owns 712,711 shares of Medpace Holdings, Inc.
- Troendle also indirectly owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by the CEO. It doesn't inherently convey positive or negative sentiment, but the market may react based on their interpretation of the sales.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, potentially impacting the stock price.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | CEO August J. Troendle sold 4,782 shares of Medpace Holdings stock. |
| 05/09/2024 | CEO August J. Troendle sold 3,486 shares of Medpace Holdings stock. |
| 05/10/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.